Multiplex Assays Market by Product (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein, Cell), Technology (Flow Cytometry, Luminescence, Application (R&D, Diagnosis), End User (Pharma & Biotech, Hospital) & Region - Global Forecasts to 2026
The multiplex assays market is projected to reach USD 4.3 billion by 2026, at a CAGR of 7.6% during the forecast period. Market growth is mainly driven by factors such as the increasing adoption of companion diagnostics, the increasing incidence of chronic and infectious diseases, the growing awareness of the disease diagnosis, and the need for effective analytical platforms in research and clinical diagnostics to reduce the operational costs and the time taken for diagnosis.
The emerging Asian markets is expected to offer strong growth opportunities for players in the market. In contrast, the high cost of multiplex assay equipment, stringent regulations and standards, and issues in the standardization of multiplex assays design are the major factors restraining the growth of this market. The global market is segmented based on product & service, type, technology, application, end user, and region.
To know about the assumptions considered for the study, Request for Free Sample Report
Multiplex Assays Market Growth Dynamics
Growth Drivers: Increasing use of multiplex assays in companion diagnostics, increasing advantages over singleplex and traditional assays, increasing incidence of chronic and infectious diseases, and growing awareness about early disease diagnosis
The multiplex assays are extensively used in the companion diagnostics, and in the drug development. The edge of the multiplex assays over the singleplex assays which includes reduced reaction tie, reagents, and analyte concentration, helps to deliver the assay result faster, and deal with the rare samples (low concentration sample). The massive prevalence of chronic and infectious diseases offers more opportunities for the market by creating more demand of multiplex assays.
Growth Opportunities: Increasing validation of the biomarkers in molecular and protein diagnostics, along with the rising need of the high-throughput and automated systems
Multiple biomarker analysis has a vast application in the area of cancer, autoimmune diseases, and neurodegenerative diseases. A large number of biomarkers are being discovered and validated, and there is a higher probability of the development of new diagnostic tests. The incoming latest technology of automated multiplex assay instrument are also expected to boost the market growth with their high efficiency and speed of delivering the accurate multiplex assay test results.
Restraints: The increasing cost of the equipment and increasing stringent regulation and standards
The high expenses of the equipment are posed challenges to the researcher and manufacturers to perform the multiplex assay testing under an affordable price. Also, the Quality control (QC) standards for multiplex assays are more stringent compared to singleplex assays.
Challenges: Dearth of skilled professionals
There is a dearth of skilled lab technicians hinder the continuous practice in clinical laboratory work
Product and Service accounted for the largest share of the multiplex assays market and is expected to grow at the highest CAGR in the forecast period.
Based on product & service, the market is segmented into instruments, consumables, and software & services. In 2020, the consumables segment is expected to account for the largest share of the market; it is also the fastest-growing segment of the global market. This can be attributed to the recurring purchase of assays and reagents for increasing research applications.
Protein-based multiplex assays segment is expected to account for the largest share of the global multiplex assays market and is expected to grow at the highest CAGR in the forecast period.
Based on type, the global market is divided into protein-based multiplex assays, nucleic acid-based multiplex assays, and cell-based multiplex assays. In 2020, the protein-based multiplex assays segment is expected to account for the largest share of the global market. This large share can be attributed to the increasing focus on proteomics studies for biomarker research and clinical diagnostics.
Flow cytometry segment is expected to account for the largest share of the global multiplex assays market and is expected to grow at the highest CAGR in the forecast period.
On the basis of technology, the global market is divided into flow cytometry, multiplex RT PCR, luminescence, fluorescence detection, and other technologies. In 2020, the flow cytometry segment is expected to account for the largest share of the global market. The large share can be attributed to the wide applications of flow cytometry in the detection and measurement of protein expression, RNA, and cell health status (cell viability & toxicity) alongside the characterization and identification of various cell types.
Research & development companies account for the largest share of the multiplex assays market in 2020 and is expected to grow at the fastest CAGR in the forecast period.
On the basis of application, the global market is divided into research & development and clinical diagnostics. In 2020, the research & development segment is expected to account for the largest share of the global market. This large share can be attributed to the wide applications of multiplex assay technologies in research & development functions.
Pharmaceutical & biotechnology companies account for the largest share of the multiplex assays market in 2020 and is expected to grow at the fastest CAGR in the forecast period.
Based on end user, the global market is segmented into pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories and other end users. In 2020, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global market. This large share can be attributed to the increasing adoption of multiplex assays in drug discovery and development by pharmaceuticals and the growing focus of biotechnology companies on developing biosimilars and monoclonal antibodies.
To know about the assumptions considered for the study, download the pdf brochure
North America was the largest regional market for the Multiplex Assays Market
The Global Market is segmented into four major regions, namely, North America (US and Canada), Europe, Asia Pacific, and Rest of the world. North America was the largest market for global market. North America is expected to account for the largest share of the global market in 2020, followed by Europe. The dominant share of the North American market is primarily attributed to its established pharmaceutical industry, presence of leading pharmaceutical and biotechnology companies, and high R&D investment.
Multiplex Assays Market Key Players
The prominent players operating in this market include Illumina, Inc. (US), Luminex Corporation (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), and Becton, Dickinson and Company (US).
Multiplex Assays Market Scope
|
Report Metric |
Details |
|
Market size available for years |
2016–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product & Service, Type, Technology, Application, End User, and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Companies covered |
Luminex Corporation (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), Qiagen N.V. (Netherlands), Abcam plc (UK), Becton, Dickinson and Company (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Meso Scale Diagnostics (US), Randox Laboratories (UK), Quanterix (US), Bio-Techne Corporation (US), Olink (Sweden), DiaSorin S.p.A. (Italy), Seegene (South Korea), Promega Corporation (US), Siemens Healthineers (Germany), PerkinElmer, Inc. (US), Shimadzu Biotech (Japan), Antigenix America, Inc. (US), Enzo Life Sciences, Inc. (US), Boster Biological Technology (US), AYOXXA Biosystems GmbH (Germany), and Cayman Chemical Company (US). |
This report categorizes the multiplex assays market into the following segments and subsegments:
By Product and Service
- Consumables
- Instruments
- Software and Services
By Type
-
Protein Multiplex Assays
- Planar Protein Assays
- Bead-Based Protein Assays
- Other Protein Assays
-
Nucleic Acid Multiplex Assays
- Planar Nucleic Acid Assays
- Bead-Based Nucleic Acid Assays
- Other Nucleic Acid Assays
- Cell-Based Multiplex Assays
By Technology
- Flow Cytometry
- Fluorescence Detection
- Luminescence
- Multiplex Real-Time PCR
- Other Technologies
By Application
-
Research & Development
- Drug Discovery & Development
- Biomarker Discovery & Validation
-
Clinical Diagnostics
- Infectious Diseases
- Cancer
- Cardiovascular Diseases
- Autoimmune Diseases
- Nervous System Disorders
- Metabolism & Endocrinology Disorders
- Other Diseases
By End User
- Pharmaceutical & Biotechnology Companies
- Hospitals & Research Institutes
- Reference Laboratories
- Other End Users
By Region
- North America
- US
- Canada
- Europe
- Asia Pacific
- Rest of the World
Recent Developments:
- In August 2021, Becton, Dickinson and Company launched its new and fully automated high-throughput diagnostic system, BD COR System. The system uses robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the US.
- In March 2021, Becton, Dickinson and Company has launched its new and fully automated high-throughput diagnostic system, BD COR System. The system uses robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the US.
- In April 2021, Illumina acquired GRAIL, which is a healthcare company focused on life-saving early detection of multiple cancers. However, Illumina will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.
- In February 2021, Thermo Fisher Scientific acquired Mesa Biotech, a privately held point-of-care molecular diagnostic company.
Frequently Asked Questions (FAQ):
What is the impact of COVID-19 on the multiplex assays market?
The COVID-19 pandemic has a positive impact on multiplex assays market. The massive demand multiplex of the SARS-CoV-2 assay such as multiplex point-of-care assays.
Who are the key players in the multiplex assays market?
The prominent players operating in this market include Illumina, Inc. (US), Luminex Corporation (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), and Becton, Dickinson and Company (US).
Which type of multiplex assay product dominates in the multiplex assays market?
The consumables segment accounts for the largest share of the market; it is also the fastest-growing segment of the multiplex assays market. This can be attributed to the recurring purchase of assays and reagents for increasing research applications.
Which type of multiplex assay type dominates in the multiplex assays market?
The protein-based multiplex assays segment accounts for the largest share of the market. This large share can be attributed to the increasing focus on proteomics studies for biomarker research and clinical diagnostics.
Which type of multiplex assay technology dominates in the multiplex assays market?
The flow cytometry segment accounts for the largest share of the market. The large share can be attributed to the wide applications of flow cytometry in the detection and measurement of protein expression, RNA, and cell health status (cell viability & toxicity) alongside the characterization and identification of various cell types.
Which type of multiplex assay application dominates in the multiplex assays market?
The research & development seg segment accounts for the largest share of the market. This large share can be attributed to the wide applications of multiplex assay technologies in research & development functions.
Which type of multiplex assay end users dominates in the multiplex assays market?
The pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global multiplex assays market. This large share can be attributed to the increasing adoption of multiplex assays in drug discovery and development by pharmaceuticals and the growing focus of biotechnology companies on developing biosimilars and monoclonal antibodies.
What factors are driving the multiplex assays market?
Market growth is largely driven by the increasing adoption of companion diagnostics, the increasing incidence of chronic and infectious diseases, the growing awareness of the disease diagnosis, and the need for effective analytical platforms in research and clinical diagnostics to reduce the operational costs and the time taken for diagnosis.
What is the market for global multiplex assays market?
The global multiplex assays market is projected to reach USD 4.3 billion by 2026 from USD 3.0 billion in 2021, at a CAGR of 7.6% during the forecast period.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 32)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 2 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.5 STAKEHOLDERS
1.6 LIMITATIONS
2 RESEARCH METHODOLOGY (Page No. - 36)
2.1 RESEARCH DATA
FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.2 PRIMARY DATA
2.2.1 KEY DATA FROM PRIMARY SOURCES
2.2.1.1 Key data from primary sources
2.2.1.2 Key industry insights
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
FIGURE 3 GLOBAL MARKET – REVENUE SHARE ANALYSIS ILLUSTRATION: ILLUMINA, INC.
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF MULTIPLEX ASSAY PRODUCTS
FIGURE 5 CAGR PROJECTIONS
FIGURE 6 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4.1 SECONDARY DATA
2.4.2 PRIMARY DATA
2.5 DATA TRIANGULATION METHODOLOGY
FIGURE 7 DATA TRIANGULATION
2.6 MARKET SHARE ANALYSIS
2.7 ASSUMPTIONS FOR THE STUDY
2.8 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY
2.8.1 COVID-19-SPECIFIC ASSUMPTIONS
2.9 LIMITATIONS
2.10 RISK ASSESSMENT
TABLE 3 RISK ASSESSMENT
2.11 COVID-19 HEALTH ASSESSMENT
2.12 COVID-19 ECONOMIC ASSESSMENT
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.14 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE GLOBAL MARKET
3 EXECUTIVE SUMMARY (Page No. - 56)
FIGURE 10 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD BILLION)
FIGURE 11 GLOBAL MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION )
FIGURE 12 GLOBAL MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
FIGURE 13 GLOBAL MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION )
FIGURE 14 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET (2021–2026)
4 PREMIUM INSIGHTS (Page No. - 60)
4.1 MULTIPLEX ASSAYS MARKET OVERVIEW
FIGURE 16 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE THE MARKET GROWTH
4.2 NORTH AMERICA: MARKET, BY APPLICATION AND COUNTRY (2020)
FIGURE 17 R&D TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
4.3 GLOBAL MARKET, BY REGION (2021 VS. 2026)
FIGURE 18 NORTH AMERICA TO DOMINATE THE GLOBAL MARKET IN 2026
4.4 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
FIGURE 19 APAC TO BE THE FASTEST-GROWING MARKET FROM 2021 TO 2026
5 MARKET OVERVIEW (Page No. - 63)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 GLOBAL MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing use of multiplex assays in companion diagnostics
5.2.1.2 Increasing advantages over singleplex and traditional assays
5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2019, 2030, AND 2045
TABLE 4 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
TABLE 5 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR THE DIAGNOSIS OF SARS-COV-2
5.2.2 RESTRAINTS
5.2.2.1 Increasing costs of equipment
5.2.2.2 Growing number of stringent regulations and standards
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics
5.2.3.2 Rising need for high-throughput and automated systems
5.2.4 CHALLENGES
5.2.4.1 Increasing dearth of skilled professionals
6 MULTIPLEX ASSAYS MARKET, BY PRODUCT AND SERVICE (Page No. - 70)
6.1 INTRODUCTION
TABLE 6 GLOBAL MARKET, BY PRODUCT AND SERVICE, 2016–2020 (USD MILLION)
TABLE 7 GLOBAL MARKET, BY PRODUCT AND SERVICE, 2021–2026 (USD MILLION)
6.2 CONSUMABLES
TABLE 8 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 9 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 11 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 12 MULTIPLEX ASSAY INSTRUMENTS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 13 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 14 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 15 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.4 SOFTWARE & SERVICES
TABLE 16 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 17 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 18 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 19 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7 MULTIPLEX ASSAYS MARKET, BY TYPE (Page No. - 77)
7.1 INTRODUCTION
TABLE 20 GLOBAL MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 21 GLOBAL MARKET, BY TYPE, 2021–2026 (USD MILLION)
7.2 PROTEIN MULTIPLEX ASSAYS
TABLE 22 PROTEIN MULTIPLEX ASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 23 PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 24 PROTEIN MULTIPLEX ASSAY MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 25 PROTEIN MULTIPLEX ASSAY MARKET, BY REGION, 2021–2026(USD MILLION)
TABLE 26 NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 27 NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.2.1 PLANAR PROTEIN ASSAYS
TABLE 28 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 29 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2021–2026(USD MILLION)
TABLE 30 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 31 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.2.2 BEAD-BASED PROTEIN ASSAYS
TABLE 32 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 33 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 34 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 35 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.2.3 OTHER PROTEIN ASSAYS
TABLE 36 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 37 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2021–2026(USD MILLION)
TABLE 38 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 39 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.3 NUCLEIC ACID MULTIPLEX ASSAYS
TABLE 40 SOME OF THE FDA AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS AUTHORIZED FOR THE SIMULTANEOUS DETECTION OF INFLUENZA VIRUSES AND SARS-COV-2
TABLE 41 NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 42 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 43 NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 44 NUCLEIC ACID MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 46 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.3.1 PLANAR NUCLEIC ACID ASSAYS
TABLE 47 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 48 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 50 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS
TABLE 51 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 52 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 54 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.3.3 OTHER NUCLEIC ACID ASSAYS
TABLE 55 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 56 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 57 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 58 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7.4 CELL-BASED MULTIPLEX ASSAYS
TABLE 59 CELL-BASED MULTIPLEX ASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 60 CELL-BASED MULTIPLEX ASSAY MARKET, BY REGION, 2021–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAY MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 62 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAY MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY (Page No. - 97)
8.1 INTRODUCTION
TABLE 63 GLOBAL MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 64 GLOBAL MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
8.2 FLOW CYTOMETRY
TABLE 65 GLOBAL MARKET FOR FLOW CYTOMETRY, BY REGION, 2016–2020 (USD MILLION)
TABLE 66 MARKET FOR FLOW CYTOMETRY, BY REGION, 2021–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2026 (USD MILLION)
8.3 FLUORESCENCE DETECTION
TABLE 69 GLOBAL MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2016–2020 (USD MILLION)
TABLE 70 MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2021–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2021–2026 (USD MILLION)
8.4 LUMINESCENCE
TABLE 73 GLOBAL MARKET FOR LUMINESCENCE, BY REGION, 2016–2020 (USD MILLION)
TABLE 74 MARKET FOR LUMINESCENCE, BY REGION, 2021–2026 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET FOR LUMINESCENCE, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET FOR LUMINESCENCE, BY COUNTRY, 2021–2026 (USD MILLION)
8.5 MULTIPLEX REAL-TIME PCR
TABLE 77 GLOBAL MARKET FOR MULTIPLEX RT PCR, BY REGION, 2016–2020 (USD MILLION)
TABLE 78 MARKET FOR MULTIPLEX RT PCR, BY REGION, 2021–2026 (USD MILLION)
TABLE 79 NORTH AMERICA: MARKET FOR MULTIPLEX RT PCR, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 80 NORTH AMERICA: MARKET FOR MULTIPLEX RT PCR, BY COUNTRY, 2021–2026 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 81 GLOBAL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016–2020 (USD MILLION)
TABLE 82 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION)
TABLE 83 NORTH AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 84 NORTH AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)
9 MULTIPLEX ASSAYS MARKET, BY APPLICATION (Page No. - 109)
9.1 INTRODUCTION
TABLE 85 GLOBAL MARKET, BY APPLICATION, 2016–2020 (USD MILLION)
TABLE 86 GLOBAL MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
9.2 RESEARCH & DEVELOPMENT
TABLE 87 GLOBAL MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2016–2020 (USD MILLION)
TABLE 88 GLOBAL MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2021–2026 (USD MILLION)
TABLE 89 GLOBAL MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2016–2020 (USD MILLION)
TABLE 90 GLOBAL MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2021–2026 (USD MILLION)
TABLE 91 NORTH AMERICA: MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 92 NORTH AMERICA: MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2021–2026 (USD MILLION)
9.2.1 DRUG DISCOVERY & DEVELOPMENT
TABLE 93 GLOBAL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2016–2020 (USD MILLION)
TABLE 94 GLOBAL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2026 (USD MILLION)
TABLE 95 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 96 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2026 (USD MILLION)
9.2.2 BIOMARKER DISCOVERY & VALIDATION
TABLE 97 GLOBAL MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2016–2020 (USD MILLION)
TABLE 98 MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2021–2026 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2021–2026 (USD MILLION)
9.3 CLINICAL DIAGNOSTICS
TABLE 101 GLOBAL MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 102 GLOBAL MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 103 GLOBAL MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION)
TABLE 104 GLOBAL MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION)
TABLE 105 NORTH AMERICA: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 106 NORTH AMERICA: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION)
9.3.1 INFECTIOUS DISEASES
TABLE 107 GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION)
TABLE 108 GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION)
TABLE 109 NORTH AMERICA: GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 110 NORTH AMERICA: GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION)
9.3.2 CANCER
TABLE 111 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 112 GLOBAL MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION)
TABLE 113 GLOBAL MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION)
TABLE 114 NORTH AMERICA: MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION)
9.3.3 CARDIOVASCULAR DISEASES
TABLE 116 GLOBAL MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION)
TABLE 117 GLOBAL MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION)
TABLE 118 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 119 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION)
9.3.4 AUTOIMMUNE DISEASES
TABLE 120 PREVALENCE OF SOME AUTOIMMUNE DISEASES
TABLE 121 GLOBAL MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION)
TABLE 122 GLOBAL MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION)
TABLE 123 NORTH AMERICA: MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 124 NORTH AMERICA: MARKET FOR AUTOIMMUNE DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION)
9.3.5 NERVOUS SYSTEM DISORDERS
TABLE 125 GLOBAL MARKET FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION)
TABLE 126 GLOBAL MARKET FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION)
TABLE 127 NORTH AMERICA: FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 128 NORTH AMERICA: FOR NERVOUS SYSTEM DISORDER DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION)
9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
TABLE 129 GLOBAL MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY REGION, 2016–2020 (USD MILLION)
TABLE 130 GLOBAL MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY REGION, 2021–2026 (USD MILLION)
TABLE 131 NORTH AMERICA: MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 132 NORTH AMERICA: MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDER DIAGNOSTICS, BY COUNTRY, 2021–2026 (USD MILLION)
9.3.7 OTHER DISEASES
TABLE 133 GLOBAL MARKET FOR OTHER DISEASES, BY REGION, 2016–2020 (USD MILLION)
TABLE 134 GLOBAL MARKET FOR OTHER DISEASES, BY REGION, 2021–2026 (USD MILLION)
TABLE 135 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 136 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2026 (USD MILLION)
10 MULTIPLEX ASSAYS MARKET, BY END USER (Page No. - 133)
10.1 INTRODUCTION
TABLE 137 GLOBAL MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 138 GLOBAL MARKET, BY END USER, 2021–2026(USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
TABLE 139 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2020 (USD MILLION)
TABLE 140 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2026 (USD MILLION)
TABLE 141 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 142 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION)
10.3 HOSPITALS & RESEARCH INSTITUTES
TABLE 143 GLOBAL MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY REGION, 2016–2020 (USD MILLION)
TABLE 144 GLOBAL MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY REGION, 2021–2026 (USD MILLION)
TABLE 145 NORTH AMERICA: MARKET FOR HOSPITAL & RESEARCH INSTITUTES, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 146 NORTH AMERICA: MARKET FOR HOSPITAL & RESEARCH INSTITUTES, BY COUNTRY, 2021–2026 (USD MILLION)
10.4 REFERENCE LABORATORIES
TABLE 147 GLOBAL MARKET FOR REFERENCE LABORATORIES, BY REGION, 2016–2020 (USD MILLION)
TABLE 148 GLOBAL MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021–2026 (USD MILLION)
TABLE 149 NORTH AMERICA: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 150 NORTH AMERICA: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)
10.5 OTHER END USERS
TABLE 151 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2016–2020 (USD MILLION)
TABLE 152 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION)
TABLE 153 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 154 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)
11 MULTIPLEX ASSAYS MARKET, BY REGION (Page No. - 143)
11.1 INTRODUCTION
TABLE 155 GLOBAL MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 156 GLOBAL MARKET, BY REGION, 2021–2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 22 NORTH AMERICA: MARKET SNAPSHOT
TABLE 157 NORTH AMERICA: MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 158 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 159 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2016–2020 (USD MILLION)
TABLE 160 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 161 NORTH AMERICA: MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 162 NORTH AMERICA: MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 163 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 164 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 165 NORTH AMERICA: MARKET, BY APPLICATION, 2016–2020 (USD MILLION)
TABLE 166 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 167 NORTH AMERICA: MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 168 NORTH AMERICA: MARKET, BY END USER, 2021–2026 (USD MILLION)
11.2.1 US
TABLE 169 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2016–2020 (USD MILLION)
TABLE 170 US: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 171 US: MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 172 US: MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 173 US: MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 174 US: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 175 US: MARKET, BY APPLICATION, 2016–2020 (USD MILLION)
TABLE 176 US: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 177 US: MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 178 US: MARKET, BY END USER, 2021–2026 (USD MILLION)
11.2.2 CANADA
TABLE 179 CANADA: MARKET, BY PRODUCT & SERVICE, 2016–2020 (USD MILLION)
TABLE 180 CANADA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 181 CANADA: MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 182 CANADA: MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 183 CANADA: MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 184 CANADA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 185 CANADA: MARKET, BY APPLICATION, 2016–2020 (USD MILLION)
TABLE 186 CANADA: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 187 CANADA: MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 188 CANADA: MARKET, BY END USER, 2021–2026 (USD MILLION)
11.3 EUROPE
TABLE 189 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2016–2020 (USD MILLION)
TABLE 190 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 191 EUROPE: MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 192 EUROPE: MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 193 EUROPE: MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 194 EUROPE: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 195 EUROPE: MARKET, BY APPLICATION, 2016–2020 (USD MILLION)
TABLE 196 EUROPE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 197 EUROPE: MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 198 EUROPE: MARKET, BY END USER, 2021–2026 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 23 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 199 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2016–2020 (USD MILLION)
TABLE 200 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 201 ASIA PACIFIC: MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 202 ASIA PACIFIC: MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 203 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 204 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 205 ASIA PACIFIC: MARKET, BY APPLICATION, 2016–2020 (USD MILLION)
TABLE 206 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 207 ASIA PACIFIC: MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 208 ASIA PACIFIC: MARKET, BY END USER, 2021–2026 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 209 ROW: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2016–2020 (USD MILLION)
TABLE 210 ROW: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
TABLE 211 ROW: MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 212 ROW: MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 213 ROW: MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 214 ROW: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 215 ROW: MARKET, BY APPLICATION, 2016–2020 (USD MILLION)
TABLE 216 ROW: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
TABLE 217 ROW: MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 218 ROW: MARKET, BY END USER, 2021–2026 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 173)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF THE STRATEGIES ADOPTED BY KEY PLAYERS IN THE MULTIPLEX ASSAYS MARKET, 2018 TO 2021
12.3 MARKET RANKING ANALYSIS, 2020
FIGURE 24 MULTIPLEX MARKET SHARE ANALYSIS, 2020
TABLE 219 GLOBAL MARKET: DEGREE OF COMPETITION
12.4 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS)
12.4.1 STARS
12.4.2 PERVASIVE PLAYERS
12.4.3 EMERGING LEADERS
12.4.4 PARTICIPANTS
FIGURE 25 GLOBAL MARKET (GLOBAL): COMPANY EVALUATION QUADRANT, 2020
12.5 COMPANY EVALUATION QUADRANT (SMES/STARTUPS)
12.5.1 PROGRESSIVE COMPANIES
12.5.2 STARTING BLOCKS
12.5.3 RESPONSIVE COMPANIES
12.5.4 DYNAMIC COMPANIES
FIGURE 26 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
12.6 COMPETITIVE SITUATION AND TRENDS
12.6.1 PRODUCT LAUNCHES AND APPROVALS
TABLE 220 PRODUCT LAUNCHES AND APPROVALS, 2018–2021
12.6.2 DEALS
TABLE 221 DEALS, 2018–2021
12.6.3 OTHER DEVELOPMENTS
TABLE 222 OTHER DEVELOPMENTS, 2018–2021
13 COMPANY PROFILES (Page No. - 186)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 ILLUMINA, INC.
TABLE 223 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 27 COMPANY SNAPSHOT: ILLUMINA, INC. (2020)
13.2 LUMINEX CORPORATION
TABLE 224 LUMINEX CORPORATION: BUSINESS OVERVIEW
FIGURE 28 LUMINEX CORPORATION: COMPANY SNAPSHOT (2020)
13.3 THERMO FISHER SCIENTIFIC INC.
TABLE 225 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 29 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC INC. (2020)
13.4 BIO-RAD LABORATORIES, INC.
TABLE 226 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2020)
13.5 BECTON DICKINSON AND COMPANY
TABLE 227 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW
FIGURE 31 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2020)
13.6 QIAGEN N.V.
TABLE 228 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: QIAGEN N.V. (2020)
13.7 ABCAM PLC
TABLE 229 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: ABCAM PLC (2020)
13.8 MERCK KGAA
TABLE 230 MERCK KGAA.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: MERCK KGAA (2020)
13.9 AGILENT TECHNOLOGIES INC.
TABLE 231 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2020)
13.1 QUANTERIX
TABLE 232 QUANTERIX.: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: QUANTERIX (2020)
13.11 DIASORIN S.P.A.
TABLE 233 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: DIASORIN S.P.A. (2020)
13.12 BIO-TECHNE CORPORATION
TABLE 234 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: BIO-TECHNE CORPORATION (2020)
13.13 MESO SCALE DIAGNOSTICS, LLC
TABLE 235 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
13.14 RANDOX LABORATORIES LTD.
TABLE 236 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
13.15 OLINK
TABLE 237 OLINK: BUSINESS OVERVIEW
13.16 OTHER PLAYERS
13.16.1 SEEGENE INC.
TABLE 238 SEEGENE INC.: COMPANY OVERVIEW
13.16.2 PROMEGA CORPORATION
TABLE 239 PROMEGA CORPORATION: COMPANY OVERVIEW
13.16.3 SIEMENS HEALTHINEERS
TABLE 240 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
13.16.4 PERKINELMER INC.
TABLE 241 PERKINELMER INC.: COMPANY OVERVIEW
13.16.5 SHIMADZU CORPORATION
TABLE 242 SHIMADZU CORPORATION: COMPANY OVERVIEW
13.16.6 ANTIGENIX AMERICA, INC.
TABLE 243 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW
13.16.7 ENZO LIFE SCIENCES, INC.
TABLE 244 ENZO LIFE SCIENCES, INC: COMPANY OVERVIEW
13.16.8 CAYMAN CHEMICAL LTD.
TABLE 245 CAYMAN CHEMICAL LTD.: COMPANY OVERVIEW
13.16.9 BOSTER BIOLOGICAL TECHNOLOGY
TABLE 246 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 255)
14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the multiplex assays market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the multiplex assays market. The secondary sources used for this study include the World Health Organization (WHO), International Cytokine & Interferon Society (ICIS), Diagnostic Marketing Association, American Clinical Laboratory Association (ACLA), and Open Journal of Clinical Diagnostics, Annual Reports, SEC Filings, Investor Presentations, and Press Releases of Key Players, White Papers, Journals/Magazines, and News Articles SEC Filings, Annual Reports, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Multiplex Assays Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the multiplex assays market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the multiplex assays business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global multiplex assays market based on the product & service, type, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiplex assays market
- To analyse opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World
- To strategically profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies
- To track and analyse competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the multiplex assays market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional 13 company profiles
Growth opportunities and latent adjacency in Multiplex Assays Market